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Finally, Montagnese et al. raise concerns about the variables to
be included in the West-Haven criteria [1]. Indeed, the criteria
presented in Table 3 [4] do not correspond to the ‘‘original’’ West
Haven criteria [6]. Unfortunately, numerous studies have
employed variations of these criteria [7]. In this review, we have
selected one of these criteria including level of consciousness,
intellectual behavior, neurological ﬁndings, and electroencepha-
lographic (EEG) abnormalities [8] in an attempt to be exhaustive.
Montagnese et al. are right in that there may not be a parallel
between consciousness, behavior, other neurological ﬁndings,
and EEG changes, which represents a limitation of these criteria.
An index score comparable to the Child–Pugh score, combining
the independent scores of these variables could be more accurate
[6]. However, no consensus exists yet on an optimal scoring
system.
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JOURNAL OF HEPATOLOGYTo the Editor:
In response to Montagnese et al. [1], we fully agree that hepatic
encephalopathy is a multifactorial syndrome which may result
from impaired liver function, portosystemic shunts as well as
from non-hepatic factors including sepsis, electrolyte imbalance,
and sedative agents. None of the manifestations of hepatic
encephalopathy are speciﬁc to any of the mechanisms involved.
Although we do not clearly understand what a ‘‘statistical deﬁni-
tion’’ means in this context, we also agree that, as it is multifac-
torial and non-speciﬁc, ‘‘hepatic encephalopathy’’ might be better
termed as ‘‘encephalopathy’’ in critically-ill cirrhotic patients
who frequently have several precipitating factors. Elevated blood
ammonia levels are the hallmark of encephalopathy in cirrhosis.
However, the correlation between blood ammonia and severity of
encephalopathy is weak [2]. In addition, due to a marked impair-
ment in liver function, any critically-ill cirrhotic patient is
expected to have elevated blood ammonia levels, whatever the
severity of encephalopathy. Practically, the ﬁndings of elevated
blood ammonia levels in this population may not exclude the
contribution of non-hepatic factors in the occurrence of neuro-
psychiatric changes. This is the reason why, in line with others
[3], we have suggested that the systematic determination of
blood ammonia levels is unlikely to be useful in the management
of critically-ill cirrhotic patients [4].
As pointed out by Montagnese et al. [1], whether or not non-
hepatic factors are involved in the occurrence of encephalopathy,
in patients with acute liver failure, is a crucial issue. Indeed, while
the prognostic value of ‘‘spontaneous’’ encephalopathy (i.e.
encephalopathy only related to impaired liver function) is
unequivocally poor in acute liver diseases, it would be highly
questionable to consider transplantation if encephalopathy is
only related to non-hepatic factors. However, the issue of patients
with acute liver failure is clearly different from that of critically-
ill cirrhotic patients. In addition, any patient with acute liver fail-
ure is expected to have high blood ammonia levels, whatever
non-hepatic factors are involved in the mechanisms of encepha-
lopathy [5]. No threshold value of blood ammonia would allow a
clear differentiation between ‘‘hepatic encephalopathy’’ and
‘‘non-hepatic encephalopathy’’. Careful analysis of the potential
contributing factors is still essential in the management ofJournal of Hepatology 2012 vol. 57 j 921–934 929
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Contrast enhanced ultrasound for the diagnosis of
hepatocellular carcinoma (HCC): Comments on AASLD guidelines
To the Editor:
Contrast enhanced ultrasound (CEUS) has been introduced
10 years ago for liver imaging in many European and Asian coun-
tries, but FDA approval in the US is still lacking [1]. The excellent
value of CEUS has been established by numerous prospective
studies including the German DEGUM-Study with over 1000
patients [2] and the respective French multicentric study [3].
CEUS was proven able to detect and characterize liver tumours
in clinical routine within at least the same accuracy range as con-
trast enhanced computed tomography (CECT) and contrast
enhanced magnetic resonance imaging (CEMRI) [4,5].
Therefore, CEUS has been introduced into important guide-
lines and recommendations, like those from the American Associ-
ation for the Study of Liver Diseases (AASLD) 2005 [6], the Asian
Paciﬁc Association for the Study of the Liver (APASL) [7], the Jap-
anese Society of Hepatology [8] and the European Federation of
Societies for Ultrasound in Medicine and Biology (EFSUMB)
guidelines 2004 [9], 2008 [10], and WFUMB-EFSUMB guidelines
2012 (in preparation). However, CEUS has been eliminated from
the diagnostic ﬂow chart of nodules in cirrhosis in the updated
AASLD guidelines 2011 [11]. This removal raised controversial
discussion and was not well received in Europe and Asia. This
is therefore the issue to which the present commentary refers.
There are two reasons for which CEUS has been eliminated
from the AASLD guidelines. 1. ‘‘Contrast-enhanced US may offer
false positive HCC diagnosis in patients with cholangiocarcinoma
and thus, has been dropped from the diagnostic techniques’’
Intrahepatic cholangiocellular carcinoma (ICC) is a rare
tumour in liver cirrhosis (about 1–3% of newly developed tumors)
[12,13] but the incidence appears raising [14]. In a retrospective
series of 21 patients with histologically conﬁrmed ICC on cirrho-
sis collected between 2003 and 2009, the Barcelona Clinic Liver
Cancer (BCLC) group found that ten ICC had the same CEUS
enhancement pattern considered diagnostic for HCC, consisting
in homogeneous arterial hyperenhancement followed by wash-
out [15]. At variance, these tumours showed hyperintense
enhancement in the arterial phase but lacked wash-out at MRI,
failing to show the typical HCC pattern, thus prompting biopsy.
The difference in the enhancement patterns is probably related
to the different pharmacokinetics of contrast agents used for US
(strictly intravascular) and MRI (extravascular space diffusion of
Gadolinium which transiently binds to ﬁbrous tissue, explaining
enhancement in ICC in the late phase) [16,17]. The valuable
observation of the BCLC group on the potential risk of false posi-
tive diagnosis of HCC in cirrhosis by CEUS has to be fully
acknowledged and kept in high consideration. However, the qual-
ity of the study and the clinical consequences of this possible risk
do not seem to justify the complete removal of CEUS from the
imaging armamentarium. The study included a relatively low
number of patients recruited over a long time of six years
(approximately only 1–2/year at risk of misdiagnosis by CEUS),
which outlines the rarity of ICC, and had a non-prospective and
non-controlled study design. This means that an incorporation
bias could have occurred. In other words, it cannot be excluded
that some ICC were erroneously diagnosed as HCC by MRI. MRI
was, in fact, the diagnostic reference standard, at least for nodules
>2 cm, with no possibility to detect false positive cases for HCC.
Furthermore, no information was reported about the behaviour
of ICC at CT [15]. Nonetheless, CT was maintained as capable of
establishing a diagnosis of HCC, despite it may show the typical
pattern of HCC also in primary liver lymphoma [18], an entity
which in some series of HCV-related cirrhosis was reported to
occur even more frequently than cholangiocarcinoma [19]. Con-
sequently, applying a required positive predictive values (PPV)
of 100% for accepting a technique as diagnostic for HCC (CEUS
was eliminated despite estimated positive predictive value
>95%) could make not only CEUS, but possibly also CT unaccept-
able, and a large prospective trial of histologically conﬁrmed nod-
ules would be required to demonstrate how accurate MRI is. It is
worth reminding, however, that in one prospective trial with his-
tology as reference standard for all patients, a total speciﬁcity of
the arterial wash-in with venous wash-out pattern for HCC in cir-
rhosis was reported [20], but the number of cases could have
been too low to conﬁrm 100% PPV.
Furthermore, it is worth pointing out that, in ICC, the pattern
of CEUS would anyway suggest a diagnosis of malignancy, for
which it is approximately totally speciﬁc [20], whereas the pat-
tern of MRI in case of ICC would not be diagnostic for malignancy
(wash-in not followed by wash-out). This is an important point,
since biopsy is not always technically feasible and it shows only
moderate sensitivity for malignancy in very small nodules (1–
2 cm) [21].
Detailed analysis of the patterns reported in the study by
which guidelines were modiﬁed [15] could be of help in better
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